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Background: Infection contributes to significant morbidity and mortality particularly in
the very young and in low- and middle-income countries. While vaccines are a highly
cost-effective tool against infectious disease little is known regarding the cellular and
molecular pathways by which vaccines induce protection at an early age. Immunity is
distinct in early life and greater precision is required in our understanding of mechanisms
of early life protection to inform development of new pediatric vaccines.
Methods and Analysis: We will apply transcriptomic, proteomic, metabolomic,
multiplex cytokine/chemokine, adenosine deaminase, and flow cytometry immune cell
phenotyping to delineate early cellular and molecular signatures that correspond to
vaccine immunogenicity. This approach will be applied to a neonatal cohort in The
Gambia (N ∼ 720) receiving at birth: (1) Hepatitis B (HepB) vaccine alone, (2) Bacille
Calmette Guerin (BCG) vaccine alone, or (3) HepB and BCG vaccines, (4) HepB and
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BCG vaccines delayed till day 10 at the latest. Each study participant will have a
baseline peripheral blood sample drawn at DOL0 and a second blood sample at
DOL1,−3, or−7 as well as late timepoints to assess HepB vaccine immunogenicity.
Blood will be fractionated via a “small sample big data” standard operating procedure that
enables multiple downstream systems biology assays. We will apply both univariate and
multivariate frameworks and multi-OMIC data integration to identify features associated
with anti-Hepatitis B (anti-HB) titer, an established correlate of protection. Cord blood
sample collection from a subset of participants will enable human in vitro modeling to
test mechanistic hypotheses identified in silico regarding vaccine action. Maternal anti-
HB titer and the infant microbiome will also be correlated with our findings which will be
validated in a smaller cohort in Papua New Guinea (N ∼ 80).
Ethics and Dissemination: The study has been approved by The Gambia
Government/MRCG Joint Ethics Committee and The Boston Children’s Hospital
Institutional Review Board. Ethics review is ongoing with the Papua New Guinea
Medical Research Advisory Committee. All de-identified data will be uploaded to public
repositories following submission of study output for publication. Feedback meetings will
be organized to disseminate output to the study communities.
Clinical Trial Registration: Clinicaltrials.gov Registration Number: NCT03246230
Keywords: markers, newborn, vaccine, immunogenicity, systems biology, OMICS
BACKGROUND AND RATIONALE FOR THE
STUDY
Infection remains a major cause of morbidity and mortality
accounting for over 30% of global deaths occurring each year in
children under the age of 5 years (1). The burden of infectious
disease is highest among the very young and in low- and middle-
income countries (1, 2). In 2017, 5.4 million deaths occurred in
children under the age of five accounting for 38.9 deaths per
thousand live births (2). Roughly 2.5million (47%) of these under
five deaths occurred in the first 28 days of life (1). The leading
causes of under-five mortality in 2016 were complications of
prematurity (18%), pneumonia (16%) intrapartum related events
(12%), congenital anomalies (9%), diarrhea (8%), neonatal sepsis
(7%), and malaria (5%) (1). Thus, infectious disease remains a
leading cause of mortality and indeed morbidity during the most
vulnerable period of life.
Immunization is a powerful and highly cost-effective
approach to prevent infection (3–5). It is estimated that for every
public dollar spent on immunization, there is a $44 return on
investment (6), and that vaccines have contributed to saving
over 20 million lives and $350 billion between 2001 and 2017
in 73 low and middle income countries alone (6). Vaccines are
Abbreviations: Ab, Antibody; BCG, Bacille Calmette-Guérin; CMI, Cell Mediated
Immunity; EPI, Expanded Programme on Immunization; EPIC-HIPC, Expanded
Programme on Immunization Consortium- Human Immune Project Consortium;
HBV, Hepatitis B virus; HepB, Hepatitis B; HB-sAg, Hepatitis B Surface antigen;
Anti-HBs, anti-Hepatitis B surface antigen; LSHTM, London School of Hygiene
and Tropical Medicine; MRCG, Medical Research Council Unit The Gambia;
PNG, Papua New Guinea; PNGIMR, Papua New Guinea Institute of Medical
Research; WBA, Whole Blood Assay.
thought to save 2–3 million lives each year worldwide (7) and
have contributed to disease eradication (8–10) with prospects
for eradicating another disease in sight (11–13). However, there
are few vaccines specifically licensed for use at the extremes
of age partly because little is known regarding the molecular
pathways by which vaccines induce protection, particularly in
the “developing” immune system of the very young (14).
Systems biology, is a powerful approach to gain deep
insight into biology and has increasingly been applied to
vaccinology to obtain insights into vaccine protection (15).
However, these powerful techniques have not been applied
to the most vulnerable: newborns in resource poor settings
(16). To meet this need, an international group of academic
biomedical centers have partnered to form the Expanded
Program on Immunization Consortium (EPIC) (Figure 1)
partnering to utilize systems biology to unravel the complex
relationships between vaccine immunogenicity via early, vaccine-
induced transcriptomic, metabolomic, proteomic, multiplex
cytokine/chemokine, adenosine deaminase and immune cell
phenotype (“OMIC”) signatures. With funding from the
United States National Institute of Health (NIH), through
National Institute of Allergy and Infectious Diseases (NIAID)
U19 Initiative for the Human Immune Project Consortium
(HIPC), the study described below will be conducted to explore
these complex relationships.
Previous EPIC pilot studies (EPIC-001) conducted at the
Medical Research Council Unit The Gambia at London School
of Hygiene and Tropical Medicine (MRCUG at LSHTM) and
the Papua New Guinea Institute of Medical Research (PNGIMR)
between 2015 and 2017 demonstrated the feasibility of measuring
robust and cogent “OMIC” readouts from small volume blood
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FIGURE 1 | Geographical distribution of partnering sites for the EPIC-002 study. An overarching administrative core, clinical core (CC), data management core (DMC),
as well as an in vitro vaccine modeling project are based at Boston Children’s Hospital (Boston, MA). Clinical Core Sites are located in The Gambia (West Africa) and
Papua New Guinea (Australasia). End-point assays are conducted in The Gambia (whole blood assay and cell mediated immunity), PNG (whole blood assay),
University of British Columbia (flow cytometry and RNASeq), BCH (multiplex cytokines/chemokines, plasma proteomics, in vitro modeling including WBA and tissue
constructs) as well as the Center for Vaccinology (CEVAC; Ghent, Belgium; anti-hepatitis B surface antigen titres).
samples to obtain “OMIC” signatures (17). Based on the pilot
data, the current EPIC research project will focus on the
immunogenicity of Hepatitis B (HepB) vaccine for which a clear
correlate of protection exists (i.e., anti-hepatitis B surface antigen
antibody (Ab) titres) (18, 19). Cell mediated immunity (CMI)
though not validated as a correlate of protection but which
appears to play a role in long-term immunity (post-primary series
titres of 10 mIU/ml or greater have been shown to correlate with
the induction of memory T helper-and B-cell responses) (20),
will also be assessed. In addition, we will examine if concomitant
vaccination with Bacille Calmette Guérin (BCG) can modulate
the response to HepB vaccine. Both vaccines are recommended
for routine use at birth in these countries and in similar settings.
The HepB vaccine is safe, immunogenic and highly effective
and is on the list of Expanded Programme on Immunization
(EPI) recommended childhood vaccines. The first dose is
recommended on the day of birth to prevent vertical and
horizontal transmission of Hepatitis B virus (HBV) (18). The
HepB vaccine has one of the best-characterized serologic
correlates of protection (CoP), and is the only clear CoP for
any neonatal vaccine (18). First described in The Gambia, this
CoP is the lower limit of the peak Ab response measured >1
month after the primary series (3 or 4 doses), defined as an
anti-Hepatitis B surface antigen (anti-HBs) Ab level of >10
mIU/mL (18, 19). Importantly, while an anti-HBs threshold of
>10 mIU/ml represents the minimal level for protection from
infection, a relationship exists in direct quantitative correlation
between Ab level and duration of protection (i.e., the higher the
anti-HBs titer the better and longer protection) (19). In addition,
there is evidence to suggest that the higher the titer after the first
dose of HepB vaccine, the higher the titer after the last dose,
and persistence (18, 19). This implies that variability in response
to the first dose (21) of HepB vaccine may predict long-term
immunogenicity (18). Substantial quantitative inter-participant
variation in absolute anti-HBs levels are the norm after each
dose of HepB vaccine as with many other vaccines. Such inter-
participant variability represents a key ingredient for meaningful
analyses using a systems vaccinology approach (21).
The neonatal HepB vaccine immune response has been
reported to be altered by co-administration of BCG, which
is co-administered as part of the standard EPI, and likely to
perturb the immune response to HepB vaccine in vivo (22, 23).
Maternal antibodies to HepB have also been documented to
impair the post vaccination immune response to HepB vaccine
in newborns (18, 24, 25). The mechanisms that underlie HepB
vaccine-induced immunogenicity in newborns, including Ab and
CMI, are incompletely characterized particularly as it relates to
variations in response.
Given the many advantages, HepB vaccine represents an ideal
model in which to decipher what governs immunogenicity in
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early life. Similar reasoning regarding HepB vaccine as a model
for systems biology have led to deciphering of mechanisms
relevant for the immune response in older adults (26). This
project will study the systems biology responses of newborns
receiving HepB vaccination with and without concomitant BCG
vaccine compared to a group of infants receiving both vaccines
later in the first week of life to allow us to observe any changes
occurring over the first week of life as a result of immune
ontogeny rather than induced by vaccination. In vitro tissue
constructs will also be set up to model the in vivo responses and
maternal antibodies will be assayed to enable correlation with the
infant responses.
The ability to show a correlation between age-specific
molecular patterns (“signatures”) and vaccine-mediated
protection (our main outcome measure) should accelerate the
development and optimization of vaccines against childhood
infections of major global health importance.
STUDY QUESTIONS, OBJECTIVES
The overall goal of the project is the characterization of vaccine-
specific “OMIC” signatures that correlate with vaccine-type
specific immunogenicity in human newborns.
The EPIC-002 study will characterize vaccine-induced
“OMIC” signatures and their relationship to HepB vaccine
CoP and characterization of the impact of BCG and maternal
antibodies (MatAbs), thereby informing development of vaccines
optimized for early life immunization.
Specific Objectives:
1. Measure adaptive immune responses to HepB vaccine,
enabling correlation of in vivo “OMIC” signatures and in
vitro vaccine Modeling assays with established correlates
of protection.
2. Characterize the pre-vaccine “OMIC” and immune in vivo
signatures that may predict immunogenicity of HepB vaccine
in human newborns.
3. Characterize the impact of HepB vaccine with or without
BCG on neonatal “OMIC” and immune in vivo signatures that
predict immunogenicity of HepB vaccine.
4. Measure maternal antibodies (MatAbs) to HBV in relation
to vaccine-induced neonatal and infant “OMIC” vaccine
signatures and adaptive responses.
5. Interrogate functional correlations identified in silico using
novel human in vitro platforms.
6. Validate identified “OMIC” signatures in a distinct and
independent newborn cohort recruited from Papua New
Guinea (PNG).
STUDY DESIGN
The program consists of two neonatal cohort studies. A
longitudinal neonatal cohort study will be conducted in The
Gambia with a total follow-up time of roughly 5 months that
serves as the program’s core study. Following completion and
analysis of The Gambian study, a validation cohort study will be
conducted in Papua New Guinea to validate the key findings of
the Gambian study. The two studies will harmonize procedures
and protocols.
Participants will be recruited within the first 24 h of life into
one of four broad groups as detailed below to receive either
HepB vaccine alone, BCG vaccine alone or both HepB and BCG
vaccines at this time point. The fourth group will have the birth
doses of vaccines deferred till a time point within the first week of
life. All infants will receive the recommended birth dose of polio
vaccine a maximum of 10 days post-vaccination depending on
the group assignment.
Two mL of venous blood will be drawn from each participant
at the point of recruitment to assess “OMIC” responses. Each
participant will have a maximum of two blood draws within the
first week of life. In the core cohort in The Gambia, infants will
be randomized into three subgroups that will have the second
blood sample collected at 1, 3, or 7 days following the initial
sampling. The cohort in The Gambia therefore consists of 12
different groups (Table 1). For the PNG cohort, all infants will
have the second blood draw on the same day of life: analysis of
The Gambia cohort will inform whether this will be at day 1, 3, or
7 of life. Subsequent visits and blood draws are as detailed in the
Clinical Cohort Table below (Table 1)
In vitro effects of the HepB vaccine and BCG vaccines
will be studied in two in vitro assays using blood derived
from the same study participants immunized in vivo: (a)
whole blood assay (WBA) run at the recruitment sites on
the day of sample collection and (b) in three-dimensional
microphysiologic tissue constructs employing cryopreserved
cord blood-derived mononuclear cells and plasma (27), enabling
in vitro mechanistic interrogation of cellular and molecular
signatures that correlate with anti-HepBsAg (anti-Hepatitis B
surface antigen) titres in vivo.
Blood samples and rectal swabs for epigenetic and
microbiome analysis will be collected and stored from
participants in The Gambia. Maternal blood samples to
enable correlation of maternal anti-HB Abs to infant responses
will also be collected.
STUDY ANALYSIS PLAN
This study aim is to identify “OMIC” signatures that correlate
with HepB vaccine responses, as assessed by anti-HB titer (a
well-established CoP), by leveraging both pre- and post-vaccine
transcriptomic, proteomic, metabolomic, and cellular profiles.
Our intention is to apply both univariate and multivariate
frameworks to identify either a ranked list of molecular features
associated with anti-HB titer or subsets of the molecular features
best able to predict anti-HB titer, respectively. We plan to derive
signatures in three distinct groups of newborns (corresponding
to the distinct vaccination schedules) and compare across
groups to gain a better understanding of the molecular basis of
adjuvantation of HepB vaccine with BCG (given before, after or
simultaneously). We further plan to derive robust multi-“OMIC”
signatures correlating with effective HepB immunization by
integrating across all available “OMIC” datasets. These signatures
will then be validated in a distinct and independent newborn
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TABLE 1 | Clinical cohort table for infants recruited in The Gambia (discovery cohort) and Papua New Guinea (validation cohort).
Table courtesy Kristin Johnson, Boston Children’s Hospital.
cohort recruited from PNG. Finally, the correlations identified
by these various in silico analyses will be tested using the novel
human in vitro platforms.
We will apply these methods to define baseline cellular
and molecular pathways/hubs/nodes that predict vaccine
immunogenicity and assess specific signatures in vitro that
provide insight into vaccine mechanisms of action (MOA).
SAMPLE SIZE/BIOSTATISTICAL
CONSIDERATIONS
The cohort design included careful consideration of statistical
power and sample size. Power calculations in the setting
of traditional OMIC designs are well-documented (28) and
we performed power calculations for OMIC platforms or
flow cytometry based on preliminary data (unpublished data).
Although we intended our tests of hypothesis to borrow strength
across data types, little has been published on statistical power
for integrative analyses or cross-platform comparisons, so this
characteristic of our design was not taken into account when
determining sample size. Power calculations were carried out
using group sizes ranging between n = 30 or n = 60 per group,
two-sided significance criterion (alpha) of 0.05, and a target 80%
power to detect.
Since preliminary data for flow cytometry were not available,
we performed a worst-case power analysis using a real-world
published data on the most variable cell subpopulation where
a significant difference was still identified comparing healthy,
immunosuppressed, and transplant-tolerant individuals (29).
This provided a lower bound of the minimum sample size
required to detect a significant difference in cell sub-populations
that could act as potential biomarkers. We found n = 30 would
result in 80% power to detect a 2.3-fold difference in the relative
abundance of a cell population, while n= 60 would result in 80%
power to detect 1.8-fold difference, assuming a balanced design.
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OMIC Analyses
We considered power to detect correlations between biomarker
signals of any type and the CoP. We assumed approximate
normality, after data transformation (e.g., log-transformation)
and calculated detectable Pearson coefficients for samples using
group size n = 30 or n = 60. We concluded that our design
offered 80% power to detect correlations between continuous
measures as small as r = 0.25–0.48. Additional parameters
were included when carrying out power calculations for the
transcriptomic analysis to account for variable coverage [e.g.,
read depth across biosamples using RNASeqPower v1.10 (28)].
Here we considered power to detect differentially abundant
transcripts between two groups and estimated within-group
standard deviation from preliminary data, as before. We found
n = 30 would result in 80% power to detect a 2.4-fold difference
in the relative abundance of a transcript, while n = 60 would
result in 80% power to detect 1.4-fold difference, assuming a
balanced design.
TRIAL REGISTRATION AND FUNDING
The study is registered on clinicaltrials.gov with registration
number NCT03246230.
The study is funded primarily by a grant received from the
U.S. National Institute of Health; Grant number U19AI118608.
These funders are not involved in study design, collection,
management or analysis and interpretation of data, or
publication of output. Additional funding is provided by
the Precision Vaccines Program, supported in part by the
Department of Pediatrics and Chief Scientific Office of Boston
Children’s Hospital.
The study will be conducted according to Declaration of
Helsinki International Conference Harmonization Good Clinical
Practice (ICH-GCP) and local ethical guidelines. Internal
governance SOP’s will be followed, and study-specific procedures
developed by the study team.
ETHICAL CONSIDERATIONS
Ethical approvals have been obtained for the core study in
The Gambia from The Gambia Government/MRCG Joint
Ethics Committee (Scientific Coordinating Committee number:
1513); for the validation study in PNG from the PNGIMR
Institute Review Board (IRB number: 18.12) and the protocol
has been approved by the PNG Medical Research Advisory
Committee (IRB number 18.14). Ethical approval has also
been obtained from the Boston Children’s Hospital Institutional
Review Board (IRB-P00024239).
PARTICIPANT SELECTION
Study Sites
In the Gambia, 720 mother-infant pairs (60 per group) will be
recruited through delivery rooms at one secondary level care
institution; The Kanifing General Hospital and one primary
health facility; The Banjullinding Health Center in The Gambia.
In PNG, 80 mother-infant pairs will be recruited at Goroka
Hospital, the only tertiary hospital in the Eastern Highland
Province of PNG. Maternal infant pairs will be recruited within
the first 24 h of the infants’ life.
Rationale for Selection of Participants
As infection is most prevalent in the newborn, the study
will target this most vulnerable group to help improve our
understanding of vaccine-induced cellular and molecular
signatures associated with vaccine-induced correlate of
protection i.e., anti-HBs Abs.
INFORMED CONSENT
Community Consent
Community consent will be sought prior to the commencement
by providing information to individuals in the communities
served by the participating health centers. Village heads and key
opinion leaders in the communities will be engaged in large
community meetings during which information regarding the
study will be provided and opportunities given to ask questions,
in line with previous practice at the MRCG and PNGIMR.
Individual Consent
Women presenting for antenatal care in the 2nd or 3rd trimester
of pregnancy will be approached at the antenatal care clinic
and given information regarding the study using a detailed
informed consent document. Individuals expressing interest in
participating will then be provided with a copy of the informed
consent document (Appendix) to take home to discuss with
their partners or other significant decision maker in the family.
Opportunities will be given to ask questions including the
provision of contact details to allow potential participants to
reach members of the study team after the clinic visit. Follow-up
contact will then bemade with each potential participant to verify
spousal assent, as male members of the family are typically key
decision makers in this setting. In addition, families will be asked
to confirm if other members of the household need to assent
including grandparents of the child in question.
When the mother of the potential participant presents
in labor or shortly following delivery, the consent signature
will be obtained, and eligibility assessed. Written consent will
be obtained from biological mothers of participants in each
mother-infant pair only. The consent process will continue
throughout the study with confirmation of willingness to
continue participation at each contact.
FUTURE USE OF STORED SAMPLES
Written informed consent will also be sought for the future use
of left-over biological samples for studies which would require
approval by the relevant ethics committees.
INCLUSION/EXCLUSION CRITERIA
Maternal
Healthy women delivering at term will be recruited into the
study. Inclusion and exclusion criteria are as detailed below.
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Inclusion
Reported gestation of at least 37 weeks
Spontaneous vaginal delivery
Written informed consent.
Exclusion
Antibiotic use in the week prior to delivery
HIV or HepB positive—Rapid test done in labor or shortly
after delivery
TB Diagnosis in mother or family member in the past 6 weeks
Severe intrapartum condition such as severe pre-eclampsia
Physicians assessment of high risk or previous contraindicative
obstetric history such as multiple early neonatal deaths.
Infant
Healthy term newborns will be recruited into the study. Details
of inclusion and exclusion criteria are as follows:
Inclusion
Healthy, term infant as determined by medical history, physical
examination, and judgment of the study physician.
Weight of 2.5 kg or greater at the time of enrolment.
Exclusion
Previous vaccination with any EPI vaccine
Major known congenital malformation
Apgar score < 8 at 5th min.
Physician assessment of potential high-risk infant including
significant risk factors for sepsis/morbidity (such as maternal
symptoms suggestive of urinary tract infection in the peri-partal
period), or macrosomia (birth weight above 4 kilograms).
RANDOMIZATION AND BLINDING
Following assessment of eligibility by the study physician,
newborns will be randomly assigned to 1 of 12 groups in The
Gambia (60 per group), and 1 of 4 groups in PNG (20 per group),
using a computer-generated block randomization sequence. In
The Gambia, the code will allow block randomization of 720
study participants into 12 groups, using random block sizes of
24 and 48. In PNG, block sizes of 8 will be used. Each study
participant will be assigned sequential identification numbers
(IDs) starting from 001 to 720 for The Gambia, and 1,001–
1,080 in PNG. A check digit character will be augmented to each
of these numbers to make up the participant IDs which will
be generated using the Damm algorithm (https://en.wikipedia.
org/wiki/Damm_algorithm; date accessed 08 November 2016).
Here the check digit numbers 0–9 will be converted to letters
A-H and J-K. The IDs for the Gambian cohort will be prefixed
with the letter “G” which stands for Gambia. The randomization
code will use the web application developed by the Statistics
and Bioinformatics department at MRCG to generate the IDs
including the check digit and prefix as detailed above (the app
is available on https://stats.mrc.gm/chkdgt-id/). Randomization
code for the PNG cohort will be generated at BCH using similar
methods. Randomization groups will be printed on cards labeled
with the participant identification number and allocated in the
sequence in which the infants will be recruited. Cards will be
sequentially allocated by clinical staff as participants are screened.
Due to the nature of randomized groups and difficulty of
blinding to randomized vaccine groups, staff in direct contact
with participants will be unblinded, while all laboratory staff
at the sites will be blinded to participants assigned group
throughout the study.
STUDY PROCEDURES
Cohort Overview
The cohort overview is detailed in Table 1.
Screening
Following the informed consent signature and pre-test
counseling, a detailed medical and pregnancy history will
be obtained from each eligible woman. Women will be screened
for Human Immunodeficiency Virus (HIV)-I and -II and
HB-sAg using rapid diagnostic tests. Individuals positive for
any of these antigens will be excluded from the study, offered
post-test counseling and referred for care as appropriate. It
will be essential to exclude HB-sAg positive mothers to ensure
that infants born to these mothers receive HepB vaccine at
birth to minimize transmission risk as recommended by the
World Health Organization (WHO). The study team will ensure
receipt of this vaccine within 24 h of life for all infants whose
mothers tested positive for HepB, but these infants will remain
excluded from further study procedures. Similarly, infants born
to HIV-positive mothers will be excluded and referred for further
management. Inclusion of HIV-exposed or positive infants could
impact on the biological signatures. Each newborn infant will
then undergo a full newborn exam to rule out obvious congenital
anomalies and other signs of ill health.
Enrolment
Eligible mother-infant pairs will be randomized to one of 12 or 4
groups in The Gambia and PNG cohorts, respectively, and study
procedures carried out as detailed below.
Follow-Up
The mother’s participation will end following this initial visit
while the infant will be followed up longitudinally over a 5-
months period as dictated by the study design detailed in Table 1.
Termination
Participation in the study will be completed 1 month after the
primary infant series vaccination, corresponding to 1-month post
the 4th dose of HepB vaccine, or following the week one follow-
up visit for infants in the delayed vaccine group (Groups 10 to 12)
in The Gambia. Participation in PNG will be complete after the
second visit for PNG; Table 1).
Early Termination
Infants will exit the study prior to the above if consent is
withdrawn; the study team can no longer reach the participant’s
caregiver and/or caregiver does not present for a visit at the clinic
(lost to follow-up); the participant moves out of the study area; or
the infant dies.
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Discontinuation Criteria
Study participation could also be discontinued for individual
participants if in the judgement of the investigator participation
poses an additional risk to the participant other than the already
anticipated minimal risk. The study could also be discontinued
following assessment by the Ethics Committee that the study
posed significant unacceptable risk to the participants based on
safety signals.
Strategies to Enhance Retention
To enhance participant retention and adherence to follow-up
schedule, a field calendar will be set up which automatically
generates the follow-up schedule in REDCap [a browser-based,
metadata-driven electronic data capture (EDC) software and
workflow methodology for designing clinical and translational
research databases (https://www.project-redcap.org)], following
enrolment. Each participant will be assigned to a field worker on
the day of enrolment. This individual will keep a record of the
follow-up schedule in their logbook. In addition, daily follow-up
calendars will be printed from REDCap by field supervisors to
ensure a double check for follow-ups. As an additional check,
the clinician will maintain a field diary on which visits can
checked off as they occur. The responsible field worker will call
the participant to remind him/her of the scheduled visit at least
24 h prior to the visit (first week of life visit) or the weekend prior
to the scheduled visit and again 24 h prior to the visit (subsequent
visits). Participants will be picked up by a study vehicle for the
first week of life visits to ease logistics during a time whenmother
and infant will be recovering from the birth process. Participants
will be encouraged to share travel plans with the responsible
field worker as soon as possible to allow for rescheduling
of visits.
Clinical/Laboratory Procedures
Blood Samples
The following samples will be collected as detailed in Table 1:
Two milliliters (ml) of blood will be collected at two
time points within the first week of life, as described above.
Immediately following blood draw into sodium heparinized tube
(BD VacutainerR, Cat. No. 368884), 200 µl of blood will be
pipetted into a tube containing 552 µl/ ucl of Paxgene R fluid
(BD Biosciences, Cat. No. 762165) for RNA stabilization in
preparation for later sequencing. The remaining sample will
be transported to the laboratory within 4 hours of collection
along with RNA sample. Whole blood will be centrifuged to
separate plasma. Plasma will be separated into 4× 100µl aliquots
for onward shipment to analytical laboratories. Homogeneity
of plasma aliquots will be ensured by first separating the
total volume, mixing using micro pipetting, and subsequently
separated into respective aliquots. Next, 900 µl of 1:1 whole
blood and RPMI Medium 1640-GlutaMAXTM-I (GibcoR, Cat.
No. 72400-047) will be aliquoted for immunophenotyping using
the SMARTube system. Lastly, the remaining blood will be
pelleted to obtain white blood cell. All fractionated samples will
be stored at −70◦C while awaiting and during shipment to
endpoint laboratories.
Two additional samples of 3ml each will be collected 30
days following enrolment and at Day 128 post enrolment which
corresponds to 28 days post the 4th dose of HBV to measure
anti-HBs Ag; a cell mediated immunity (CMI) assay will also
be conducted using these samples. All samples will be collected
by drip method into commercial tubes heparinized with sodium
heparin (BD vacutainers).
Cord blood samples will be collected from a random subset
of participants determined by logistics; where the mother has
signed consent prior to delivery of the placenta and the infant
is subsequently found eligible for enrolment. A total of 20
pristine cord blood samples will be targeted for collection at
each site.
Rectal Swabs
Rectal swabs will be collected at the first study visit (within
24 h of life) if the child has passed meconium, and subsequently
during the second visit (24 h, 72 h, or 7 days post first study
visit) and at Day 30 post-enrolment to enable exploration of
the infant microbiome. The swabs (FLOQSwabs (Copan, Cat.
No. 608CS01R) will be collected using standard swabs and
placed directly in 1ml of guanidine thiocyanate transport media.
They will be stored at −70◦C before and during transport to
analytical laboratories.
Vaccinations
Infants will be randomized into 1 of 4 groups (each split into
3 further subgroups to reflect day of second blood sample
collection in The Gambia), to receive vaccinations as detailed
in Table 1. Although not routinely recommended in PNG,
the infants at this site will also receive bivalent oral polio
vaccine within the first week of life as part of our efforts to
harmonize schedules.
All subsequent childhood vaccines will be given in line with
the World Health Organization (WHO) recommended EPI
schedule, including 13-valent pneumococcal conjugate vaccine,
rotavirus vaccine, Pentavalent vaccine containing diphtheria,
whole cell pertussis, tetanus toxoid, HepB and Haemophilus
influenzae type b antigens, oral polio vaccine and inactivated
polio vaccine, as detailed inTable 1. Of note, the routine schedule
in The Gambia involves vaccinations at 2, 3, and 4 months of age
beyond the birth doses (Supplementary Table 1A), while that
of PNG is 1, 2, and 3 months (Supplementary Table 1B). In
an effort to harmonize between the two study sites, the WHO
schedule of 6, 10, and 14 weeks will be utilized at both sites, and
the rotavirus vaccine (Rotarix), not routinely given in PNG, will
be administered. While there is heterogeneity between vaccines
formulations routinely used in the two countries, vaccines
from the same manufacturers will be utilized for both sites.
The routine EPI schedules for both countries are detailed in
Supplementary Tables 1A,B.
The specific vaccines which will be utilized for the study are
detailed in Tables 2, 3.
Laboratory Assays
The following assays are planned on samples collected
(Supplementary Figure 1):
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TABLE 2 | Vaccines to be studied in EPIC-002.
Vaccine Acronym Source Type Route Adjuvant
Hepatitis B
vaccine
HepB
vaccine
SIIL Sub-unit IM Alum
DwPT-HepB-Hib
(HepB
component)
Pentavalent
vaccine
SIIL Killed/toxoid IM Aluminum
phosphate
Bacille
Calmette–Guérin
BCG SIIL Live ID Self-
adjuvanted live
attenuated
vaccine
Ab, antibody; ID, intradermal; IM, intramuscular; EPI, WHO Expanded Programme on
Immunization; DwPT-HepB-Hib, Diphtheria, whole cell pertussis, tetanus, Hepatitis B and
Haemophilus influenza type b vaccine; SIIL, Serum institute of India Limited.
TABLE 3 | Other vaccines to be received during the EPIC-002 study.
Vaccine Acronym Source Type Route
Oral polio vaccine OPV SIIL Killed Oral
Inactivated polio vaccine IPV SIIL Live IM
13 -valent Pneumococcal Conjugate Vaccine PCV13 Pfizer Killed IM
Rotavirus vaccine Rotarix GSK Live Oral
ID, intradermal; IM, intramuscular; EPI, WHO Expanded Programme on Immunization;
SIIL, Serum Institute of India Ltd.; GSK, GlaxoSmithKline; IPV, Inactivated polio vaccine;
OPV, Oral polio vaccine; PCV13, 13-vallent pneumococcal conjugate vaccine.
Transcriptomics
RNA Sequencing (RNASeq) at the University of British
Columbia (UBC) Vancouver to assess the changes in gene
expression in the blood samples collected within the first week
of life.
Proteomics
Plasma samples will be subjected to nanospray liquid
chromatography tandem mass spectrometry (LC-
MS/MS) at Boston Children’s Hospital (BCH) for protein
identification and quantification by liquid chromatography
mass spectrometry.
Flow cytometry
Flow cytometry will be run by UBC/TKI to analyze the changes
in cell composition in the samples collected within the first week
of life.
Basal plasma cytokines
Plasma samples will be analyzed utilizing multiplex
cytokine assays to quantify cytokine and chemokine plasma
concentrations across the first week of life using a custom
multiplex kit (Milliplex MAP Kit: Human Cytokine/Chemokine
Magnetic Bead Panel HCYTMAG60K-PX41) at BCH.
Cell mediated immunity (CMI)
Assays will be carried out at MRCG to assess the antigen-specific
CD4 T-cell response following HepB and BCG vaccines for the
Gambian cohort only.
In vitro modeling of vaccine responses using cord
whole blood assays (WBAs; at MRCG and BCH) and
microphysiologic tissue constructs (TCs) will be conducted
at BCH.
Microbiome
Fecal (stool) microbiome composition and functional potential
will be determined over the first month of life via 16S amplicon
sequencing as well as metagenomics on selected samples to
capture changes in association with vaccine responses.
Metabolomics
Plasma metabolomics will be analyzed using Metabolon’s
HD4 platform LC-MS/MS for identification of global
plasma metabolites.
Epigenetics
To compare differential gene methylation patterns (epigenetics)
following vaccination genome-wide changes in the epigenome
will be assessed via the Infinitum Methylation EPIC bead array.
The analytical laboratory for this assay is yet to be determined.
Sample Management
Sample management and tracking will use ItemTracker; a sample
tracking and management system (http://www.itemtracker.com)
to track samples from the point of collection to the analytic
laboratories by scanning a sample-specific barcode which carries
a unique sample identifier (visit ID).
SAFETY CONSIDERATIONS AND
OVERSIGHT
Risks and Benefits
We recently reported major cellular and molecular
changes which occur over the first week of life
demonstrating a dynamic baseline (17). For this reason,
we will have a delayed vaccination group in order to
distinguish basic immune ontogeny signatures from
vaccine-induced changes.
To minimize risks, we will carefully screen mothers and
infants to avoid any risk for the infants included in the
delayed vaccination group by the following measures: (a)
only newborns to HB-sAg negative mothers will be included;
(b) any women with history of tuberculosis (TB) or TB
contact will be excluded; (c) BCG vaccination is recommended
for any time before 3 months of age and infants within
the delayed vaccination group will be vaccinated within 10
days of birth. There is indeed evidence to suggest that
delayed BCG vaccination may actually be beneficial (30). The
continued recommendation for birth doses of the vaccine
is to ensure coverage and avoid missed opportunities for
vaccination during contact with a health facility. Polio vaccine
is recommended at birth in The Gambia and will be delayed
by a maximum of 10 days for all infants in our cohort. This
infection has not been diagnosed in The Gambia for over
20 years. The risk posed from this slight delay is therefore
considered minimal.
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FIGURE 2 | Field algorithm for management of intercurrent illness during the EPIC-002 study. Green, amber and red signs are as defined in Supplementary Table 2.
Overall, the Ethics Committees have determined that
the study to pose minimal risk to participants, consisting
of transient pain when drawing blood and possibly mild
discomfort during the rectal swab. Rare complications
could include bleeding from or inflammation/infection of
puncture sites.
There are no direct benefits for the individual participants
other than access to care at the research facility allowing for
closer surveillance and higher likelihood of detecting illness
early. Participants excluded due to maternal HepB positivity
will have the added benefit of accessing the HepB vaccine
within 24 h after birth from the study team. Despite being
recommended by WHO, this practice is not yet uniformly
carried out in many low-income countries including The Gambia
and PNG, and largely depends on whether the child is born
during working hours vs. the weekend and/or late night. In
addition, in The Gambia vaccinations given after the tradition
of infant naming at the age of 7 days of age is a common
local practice also contributing to delayed vaccinations in the
real-life setting.
All costs related to medical care of participants will be covered
by the study for the duration of the study. Institutional insurance
for participants exists for all research projects conducted at the
MRCG Unit. Sponsors cover insurance for study participants at
the site in PNG.
Safety Oversight
Since the study infants are enrolled at an age at which they
are particularly prone to illness, including infections, rigorous
clinical oversight will be ensured. Oversight for participant safety
will be provided by the lead study pediatrician with support from
a local safety monitor—a pediatrician with experience caring for
children at this age who could provide input as an independent
party, in The Gambia, and a pediatrician affiliated with Goroka
Hospital in PNG.
Field staff will conduct a home visit during the first week
of life to evaluate for sick infants, such that all participants
will have a total of 2 visits (home or clinic) prior to day 7 of
life. Participants will also receive phone numbers at the point
of enrolment to enable them reach study staff in the event
of emergencies/concerns. Field staff trained to identify danger
signs will utilize an escalation system where clinical signs are
categorized into green (low risk), amber (intermediate risk),
or red (high risk) as detailed in Supplementary Table 2 and
Figure 2 to ensure prompt care for intercurrent illnesses.
DATA HANDLING, RECORDS, AND
ANALYSIS PLATFORMS
In The Gambia, all data will be collected using electronic case
report forms (CRFs) with built-in quality checks designed on
REDCap except for consent forms and certified copies of medical
records. Data capture using this platform could be done online
or offline to allow entry in settings where internet access is
suboptimal. In PNG, data will first be collected using paper
CRFs before entry into an electronic REDCap database. Data
will be prioritized into three Tiers: Tier-1 data considered
essential to accomplish primary study objectives; Tier-2 data
considered potentially useful for identifying confounders which
might influence analysis of the primary study questions and to
address secondary study questions; and Tier-3 data considered
additional exploratory data. Data will be checked for congruency
and completeness at the site and quality control (QC) checks
will be completed by data assistants and a data manager at
MRCG and PNGIMR. Queries will be generated and resolved
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by responsible staff, following which data forms will be locked
by delegated personnel to prevent inadvertent changes. This will
be followed by data extraction prioritized from Tier-1 to−3, and
data will be sent securely to the centralized Data Management
Core (DMC) at BCH. Further quality assurance (QA) processes
will be performed by the DMC and queries raised to allow
resolution of discrepancies/clarify unclear details prior to data
sharing across the project. Following this process for all tiers of
data, the database will be locked, and data downloads will be
restricted to read-only access.
The DMC will use an innovative operational structure for
data curation and integrative analysis. The digital backbone of
the DMC will leverage an institutional partnership with Amazon
Web Services (AWS) to provide secure dedicated cloud-based
access and computational tools to research programs based at
BCH. This will allow for controlled and timely updates of key
infrastructure components, resources, and policies.
CONFIDENTIALITY
All electronic data capture will be performed using secure
password-protected encrypted devices. Papers records including
consent forms, and medical records will be stored in locked
cabinets in secure locations with restricted access at the
study sites.
QUALITY CONTROL AND QUALITY
ASSURANCE
Written Standard Operating Procedures (SOPs) and Study
Specific Procedures (SSPs) will be developed and implemented
for each activity. Staff engaged in the activity will be trained to
carry out the specific procedure in accordance with the written
SOPs and SSPs. Copies of these procedures will then be provided
to each staff member for reference and additional copies will be
located at each study site for ease of reference.
A number of general QC and QA measures will be observed
for the study including: (a) having study staff work in pairs
and cross check one another’s procedures and entries, including
checking all procedures and entries before marking as complete;
(b) having senior team members validate procedures and
entries carried out by junior members and conduct spot checks
for ongoing work of junior team members; (c) disallowing
any blank fields on completed forms to ensure that where
data is not available this is clearly documented and not just
an omission in entry; and (d) requiring transmittal logs for
materials/samples transported from one location to another to
ensure that these can be tracked to their current location at
all times.
Laboratory Quality Control Measures
Controls and standards will be run for each assay. In
addition, to minimize batch effects related to laboratory
assays, additional Universal Reference Standard (URS) samples
will be included with each batch of samples to allow
comparison or data normalization to minimize potential run-
to-run or plate-to-plate variation. As a further measure to
reduce batch effects and mitigate potential confounding of
these effects across platforms, sample batches for all “OMIC”
platforms will be aligned with the study block randomization
as follows:
- Each sample batch will include two study visits per study
participant to minimize variation across time points;
- Sample batches will be generated and assigned using 48 or
96 samples (i.e., 24–48 participants over two visits) per block,
with equal representation of each of the 12 vaccine sub-groups
within each sample batch;
- Each assay team will predefine criteria for quality control of
each experimental sample and assay to ensure data quality.
The overall approach will be to have each endpoint laboratory
define its own quality control (QC) procedures with additional
quality assurance (QA) performed by the centralized Data
Management Core at BCH.
DISSEMINATION POLICY
All data will be uploaded to public repositories such as NIAID
ImmPort, https://immport.org and Gene Expression Omnibus
(GEO) and will be publicly available following submission of
study output for publication.
Study output will be published by the study team adhering to
IJMCE authorship criteria in peer reviewed journals. Results will
be disseminated at conferences and stakeholder meetings.
Community feedback will be undertaken to disseminate study
results to participating communities.
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AUTHOR CONTRIBUTIONS
OL, TK, and BK conceived the study. OL, TK, BK, RH, HS, RB,
PR, ST, and AO developed study design. OI and AB developed
protocol draft and contributed to study design. OI, OL, TK, BK,
CS, KS, AB, and AO development of protocol content. OI and BK
provide clinical oversight and developed site clinical protocols
and procedures. All authors critical review of protocol content
and review of final draft.
FUNDING
This study was funded primarily by a grant received from
the U.S. National Institute of Health; Grant number: NIAID
U19AI118608. These funders are not involved in study design,
collection, management or analysis and interpretation of data,
or publication of output. Additional funding is provided by
the Precision Vaccines Program, supported in part by the
Frontiers in Pediatrics | www.frontiersin.org 11 April 2020 | Volume 8 | Article 197
Idoko et al. Clinical Protocol Vaccine Immunogenicity in Newborns
Department of Pediatrics and Chief Scientific Office of Boston
Children’s Hospital.
ACKNOWLEDGMENTS
The authors acknowledge the study communities and staff of
the study sites involved in preparing the sites. Authors also
acknowledge all members of the EPIC Consortium and Kristin
Johnson of Boston Children’s Hospital for graphical support with
Table 1, and Figures 1 and 2.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fped.
2020.00197/full#supplementary-material
REFERENCES
1. United Nations InterAgency Group on ChildMortality Estimation. Levels and
Trends in Child Mortality (2017).
2. Global Burden of Disease. Global, regional, and national age-sex specific
mortality for 264 causes of death, 1980-2016: a systematic analysis for
the Global Burden of Disease Study 2016. Lancet. (2017). 390:1151–210.
doi: 10.1016/S0140-6736(17)32152-9
3. Duclos P, Okwo-Bele JM, Gacic-Dobo M, Cherian T. Global immunization:
status, progress, challenges and future. BMC Int Health Hum Rights. (2009) 9
(Suppl. 1):S2. doi: 10.1186/1472-698X-9-S1-S2
4. Ozawa S, Stack ML. Public trust and vaccine acceptance–
international perspectives. Hum Vaccin Immunother. (2013) 9:1774–8.
doi: 10.4161/hv.24961
5. Idoko OT, Kochhar S, Agbenyega TE, Ogutu B, Ota MO. Impact, challenges,
and future projections of vaccine trials in Africa. Am J Trop Med Hyg. (2013)
88:414–9. doi: 10.4269/ajtmh.12-0576
6. Ozawa S, Clark S, Portnoy A, Grewal S, Stack ML, Sinha A, et al.
Estimated economic impact of vaccinations in 73 low- and middle-
income countries, 2001-2020. Bull World Health Organ. (2017) 95:629–38.
doi: 10.2471/BLT.16.178475
7. Delany I, Rappuoli R, De Gregorio E. Vaccines for the 21st century. EMBO
Mol Med. (2014) 6:708–20. doi: 10.1002/emmm.201403876
8. Birn AE. Small(pox) success? Cien Saude Colet. (2011) 16:591–7.
doi: 10.1590/S1413-81232011000200022
9. Okwo-Bele JM, Cherian T. The expanded programme on immunization: a
lasting legacy of smallpox eradication. Vaccine. (2011) 29 (Suppl. 4):D74–9.
doi: 10.1016/j.vaccine.2012.01.080
10. Henderson DA. The eradication of smallpox–an overview of the
past, present, and future. Vaccine. (2011). 29 (Suppl. 4):D7–9.
doi: 10.1016/j.vaccine.2011.06.080
11. Bagcchi S. Polio endgame: overcoming the final barriers. Lancet Infect Dis.
(2016). 16:644. doi: 10.1016/S1473-3099(16)30093-7
12. Garon J, Seib K, Orenstein WA, Ramirez Gonzalez A, Chang Blanc D,
Zaffran M, et al. Polio endgame: the global switch from tOPV to bOPV.
Expert Rev Vaccines. (2016) 15:693–708. doi: 10.1586/14760584.2016.11
40041
13. Patel M, Menning L, Bhatnagar P. Polio eradication and endgame plan -
victory within grasp. Indian Pediatr. (2016) 53 (Suppl. 1):S28–32.
14. Kollmann TR, Kampmann B,Mazmanian SK,Marchant A, Levy O. Protecting
the newborn and young infant from infectious diseases: lessons from immune
ontogeny. Immunity. (2017) 46:350–63. doi: 10.1016/j.immuni.2017.03.009
15. Hagan T, Pulendran B.Will systems biology deliver its promise and contribute
to the development of new or improved vaccines? From data to understanding
through systems biology. Cold Spring Harb Perspect Biol. (2018) 10:a028894.
doi: 10.1101/cshperspect.a028894
16. Amenyogbe N, Levy O, Kollmann TR. Systems vaccinology: a promise for
the young and the poor. Philos Trans R Soc Lond B Biol Sci. (2015) 370.
doi: 10.1098/rstb.2014.0340
17. Lee AH, Shannon CP, Amenyogbe N, Bennike TB, Diray-Arce J, Idoko
OT, et al. Dynamic molecular changes during the first week of human life
follow a robust developmental trajectory. Nat Commun. (2019) 10:1092.
doi: 10.1038/s41467-019-08794-x
18. Schillie SF, Murphy TV. Seroprotection after recombinant hepatitis B
vaccination among newborn infants: a review. Vaccine. (2013) 31:2506–16.
doi: 10.1016/j.vaccine.2012.12.012
19. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B
antibody is protective? J Infect Dis. (1999) 179:489–92. doi: 10.1086/314578
20. Stubbe M, Vanderheyde N, Goldman M, Marchant A. Antigen-specific
central memory CD4+ T lymphocytes produce multiple cytokines
and proliferate in vivo in humans. J Immunol. (2006) 177:8185–90.
doi: 10.4049/jimmunol.177.11.8185
21. Tsang JS. Utilizing population variation, vaccination, and systems biology
to study human immunology. Trends Immunol. (2015). 36:479–93.
doi: 10.1016/j.it.2015.06.005
22. Ota MO, Vekemans J, Schlegel-Haueter SE, Fielding K, Sanneh M, Kidd M,
et al. Influence of Mycobacterium bovis bacillus calmette-guerin on antibody
and cytokine responses to human neonatal vaccination. J Immunol. (2002)
168:919–25. doi: 10.4049/jimmunol.168.2.919
23. Ritz N, Mui M, Balloch A, Curtis N. Non-specific effect of Bacille Calmette-
Guerin vaccine on the immune response to routine immunisations. Vaccine.
(2013) 31:3098–103. doi: 10.1016/j.vaccine.2013.03.059
24. Hu Y, Wu Q, Xu B, Zhou Z, Wang Z, Zhou YH. Influence of
maternal antibody against hepatitis B surface antigen on active immune
response to hepatitis B vaccine in infants. Vaccine. (2008) 26:6064–7.
doi: 10.1016/j.vaccine.2008.09.014
25. Van Herck K, Van Damme P. Benefits of early hepatitis B immunization
programs for newborns and infants. Pediatr Infect Dis J. (2008) 27:861–9.
doi: 10.1097/INF.0b013e318173966f
26. Fourati S, Cristescu R, Loboda A, Talla A, Filali A, Railkar R, et al.
Pre-vaccination inflammation and B-cell signalling predict age-related
hyporesponse to hepatitis B vaccination. Nat Commun. (2016) 7:10369.
doi: 10.1038/ncomms10369
27. Sanchez-Schmitz G, Stevens CR, Bettencourt IA, Flynn PJ, Schmitz-Abe
K, Metser G, et al. Microphysiologic human tissue constructs reproduce
autologous age-specific BCG and HBV primary immunization in vitro. Front
Immunol. (2018) 9:2634. doi: 10.3389/fimmu.2018.02634
28. Hart SN, Therneau TM, Zhang Y, Poland GA, Kocher JP. Calculating sample
size estimates for RNA sequencing data. J Comput Biol. (2013) 20:970–8.
doi: 10.1089/cmb.2012.0283
29. Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, et al.
Identification of a B cell signature associated with renal transplant tolerance
in humans. J Clin Invest. (2010) 120:1836–47. doi: 10.1172/JCI39933
30. Kagina BM, Abel B, Bowmaker M, Scriba TJ, Gelderbloem S, Smit E, et al.
Delaying BCG vaccination from birth to 10 weeks of age may result in
an enhanced memory CD4T cell response. Vaccine. (2009) 27:5488–95.
doi: 10.1016/j.vaccine.2009.06.103
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Idoko, Smolen, Wariri, Imam, Shannon, Dibassey, Diray-Arce,
Darboe, Strandmark, Ben-Othman, Odumade, McEnaney, Amenyogbe, Pomat, van
Haren, Sanchez-Schmitz, Brinkman, Steen, Hancock, Tebbutt, Richmond, van den
Biggelaar, Kollmann, Levy, Ozonoff and Kampmann. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pediatrics | www.frontiersin.org 12 April 2020 | Volume 8 | Article 197
Idoko et al. Clinical Protocol Vaccine Immunogenicity in Newborns
APPENDICES
1. Informed consent document version 3.1 of 16 Feb 2018
(MRCG) and version 1.0 of 19 September 2018 (PNG)
2. Algorithm for identifying danger signs among study
participants adapted from National Institute for Health and
Care Excellence (NICE) guideline.
3. Routine EPI schedule for The Gambia and PNG
4. Sample processing flow chart
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